Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Autor: Baker T; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sharifian H; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Newcombe PJ; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Gavin PG; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA., Lazarus MN; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Ramaswamy M; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA., White WI; Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA., Ferrari N; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Muthas D; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Tummala R; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA., Morand EF; Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia., Furie RA; Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA., Vital EM; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Chamberlain C; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Platt A; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Al-Mossawi H; Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA., Brohawn PZ; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA., Csomor E; Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK eszter.csomor@astrazeneca.com.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Jul 15; Vol. 83 (8), pp. 1018-1027. Date of Electronic Publication: 2024 Jul 15.

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.

Autor: Lazarus MN; Centre for Rheumatology, University College London, 5 University Street, London WC1E 6JF, UK., Turner-Stokes T, Chavele KM, Isenberg DA, Ehrenstein MR

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2012 Jul; Vol. 51 (7), pp. 1208-15. Date of Electronic Publication: 2012 Feb 15.

Wegener's granulomatosis presenting with an acute ST-elevation myocardial infarct (STEMI).

Autor: Lazarus MN, Khurana R, Sethi AS, Naughton MA

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2006 Jul; Vol. 45 (7), pp. 916-8. Date of Electronic Publication: 2006 May 16.